Regulation of p53wt glioma cell proliferation by androgen receptor-mediated inhibition of small VCP/p97-interacting protein expression
Date
2017Journal
OncotargetPublisher
Impact Journals LLCType
Article
Metadata
Show full item recordAbstract
The incidence of glioma in men is higher than that in women; however, little is known about the expression and basic function of the androgen receptor (AR) in gliomas. AR inhibited the small VCP/p97-interacting protein (SVIP) on the transcriptional level was previously reported. The present study shows that the protein level of AR is highly expressed in cell lines of the nervous system. Moreover, the AR expression is increased while SVIP expression is decreased in tumor tissue of glioma patients, which is in agreement with the progressing WHO grades. A statistically significant increase in serum testosterone level of glioma patients compared with that of non-cancer patients was also detected. Furthermore, it has been proved that SVIP is down-regulated as well as AR is up-regulated in glioma cell lines with R1881 treatment. Interestingly, the depletion of SVIP using siRNA facilitated cell proliferation and decreased p53 expression. In addition, overexpression of SVIP increased cell death only in p53wt cell lines. Moreover, U87MG cells, p53wt cell line was susceptible to AR antagonists in vitro and in vivo. The current study provides insight into the biological role of AR in suppressing SVIP and p53 and promoting the progression of glioma as well as the clinical treatment of glioma patients.Sponsors
The study was funded by the National Natural Science Foundation of China (NSFC 31201070) and China Postdoctoral Science Foundation (204001-5) to Yang Wang. The study was also funded by the National Natural Science Foundation of China (NSFC 81341074) to Shengyun Fang.Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85017011837&doi=10.18632%2foncotarget.15509&partnerID=40&md5=3b8d907cfb4ba67290fa4d51f6dcef15; http://hdl.handle.net/10713/10024ae974a485f413a2113503eed53cd6c53
10.18632/oncotarget.15509